Biosafety materials: Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system

Yuquan Zhang; Ziyue Li; Julien Milon Essola; Kun Ge; Xuyan Dai; Huining He; Haihua Xiao; Yuhua Weng; Yuanyu Huang

doi:10.1016/j.bsheal.2022.03.010

Biosafety materials: Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system

Yuquan Zhang, Ziyue Li, Julien Milon Essola, Kun Ge, Xuyan Dai, Huining He, Haihua Xiao, Yuhua Weng^*, Yuanyu Huang

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

12 Citations (Scopus)

Abstract

Despite multiple virus outbreaks over the past decade, including the devastating coronavirus disease 2019 (COVID-19) pandemic, the lack of accurate and timely diagnosis and treatment technologies has wreaked havoc on global biosecurity. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has the potential to address these critical needs for tackling infectious diseases to detect viral nucleic acids and inhibit viral replication. This review summarizes how the CRISPR/Cas system is being utilized for the treatment and diagnosis of infectious diseases with the help of biosafety materials and highlights the design principle and in vivo and in vitro efficacy of advanced biosafety materials used to deal with virus attacks.

Original language	English
Pages (from-to)	70-78
Number of pages	9
Journal	Biosafety and Health
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.bsheal.2022.03.010
Publication status	Published - Apr 2022

Keywords

Biosafety materials
CRISPR/Cas
Diagnosis
Infectious disease
SARS-CoV-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bsheal.2022.03.010

Cite this

@article{4375f1270f254b8eb4a3f8e1f29d7583,

title = "Biosafety materials: Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system",

abstract = "Despite multiple virus outbreaks over the past decade, including the devastating coronavirus disease 2019 (COVID-19) pandemic, the lack of accurate and timely diagnosis and treatment technologies has wreaked havoc on global biosecurity. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has the potential to address these critical needs for tackling infectious diseases to detect viral nucleic acids and inhibit viral replication. This review summarizes how the CRISPR/Cas system is being utilized for the treatment and diagnosis of infectious diseases with the help of biosafety materials and highlights the design principle and in vivo and in vitro efficacy of advanced biosafety materials used to deal with virus attacks.",

keywords = "Biosafety materials, CRISPR/Cas, Diagnosis, Infectious disease, SARS-CoV-2",

author = "Yuquan Zhang and Ziyue Li and {Milon Essola}, Julien and Kun Ge and Xuyan Dai and Huining He and Haihua Xiao and Yuhua Weng and Yuanyu Huang",

note = "Publisher Copyright: {\textcopyright} 2022 Chinese Medical Association (CMA)",

year = "2022",

month = apr,

doi = "10.1016/j.bsheal.2022.03.010",

language = "English",

volume = "4",

pages = "70--78",

journal = "Biosafety and Health",

issn = "2590-0536",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Biosafety materials

T2 - Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system

AU - Zhang, Yuquan

AU - Li, Ziyue

AU - Milon Essola, Julien

AU - Ge, Kun

AU - Dai, Xuyan

AU - He, Huining

AU - Xiao, Haihua

AU - Weng, Yuhua

AU - Huang, Yuanyu

PY - 2022/4

Y1 - 2022/4

N2 - Despite multiple virus outbreaks over the past decade, including the devastating coronavirus disease 2019 (COVID-19) pandemic, the lack of accurate and timely diagnosis and treatment technologies has wreaked havoc on global biosecurity. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has the potential to address these critical needs for tackling infectious diseases to detect viral nucleic acids and inhibit viral replication. This review summarizes how the CRISPR/Cas system is being utilized for the treatment and diagnosis of infectious diseases with the help of biosafety materials and highlights the design principle and in vivo and in vitro efficacy of advanced biosafety materials used to deal with virus attacks.

AB - Despite multiple virus outbreaks over the past decade, including the devastating coronavirus disease 2019 (COVID-19) pandemic, the lack of accurate and timely diagnosis and treatment technologies has wreaked havoc on global biosecurity. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has the potential to address these critical needs for tackling infectious diseases to detect viral nucleic acids and inhibit viral replication. This review summarizes how the CRISPR/Cas system is being utilized for the treatment and diagnosis of infectious diseases with the help of biosafety materials and highlights the design principle and in vivo and in vitro efficacy of advanced biosafety materials used to deal with virus attacks.

KW - Biosafety materials

KW - CRISPR/Cas

KW - Diagnosis

KW - Infectious disease

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85127459194&partnerID=8YFLogxK

U2 - 10.1016/j.bsheal.2022.03.010

DO - 10.1016/j.bsheal.2022.03.010

M3 - Review article

AN - SCOPUS:85127459194

SN - 2590-0536

VL - 4

SP - 70

EP - 78

JO - Biosafety and Health

JF - Biosafety and Health

IS - 2

ER -

Biosafety materials: Ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this